NCT06375031

Comparison of HR011408 and NovoRapid® in Subjects With Diabetics

Comparing Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid® in Subjects With Diabetics- A Randomized, Double-Blind, Three-cycle Crossover Phase I Clinical Trial

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

The objective of the study is to compare the pharmacokinetics and pharmacodynamics between HR011408 and NovoRapid® in Subjects with Diabetics.

Conditions

• Diabetes

Interventions

Type	Name	Description
DRUG	HR011408 injection; HR011408 injection Placebo	Medication regimen-A: HR011408 injection, ante cibum; HR011408 injection Placebo , post cibum
DRUG	NovoRapid®; HR011408 injection Placebo	Medication regimen-B: NovoRapid®, ante cibum; HR011408 injection Placebo, post cibum
DRUG	HR011408 injection Placebo; HR011408 injection	Medication regimen-C: HR011408 injection Placebo, ante cibum: HR011408 injection, post cibum

Timeline

• Start date: 2024-05-01
• Primary completion: 2024-07-01
• Completion: 2024-07-15
• First posted: 2024-04-19
• Last updated: 2024-05-21

Locations

1 site across 1 country: China